Cargando…

Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database

We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within the National Health Fund program and reported in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamzer, Aleksandra, Waligora, Marcin, Kopec, Grzegorz, Ptaszynska-Kopczynska, Katarzyna, Kurzyna, Marcin, Darocha, Szymon, Florczyk, Michal, Mroczek, Ewa, Mularek-Kubzdela, Tatiana, Smukowska-Gorynia, Anna, Wrotynski, Michal, Chrzanowski, Lukasz, Dzikowska-Diduch, Olga, Perzanowska-Brzeszkiewicz, Katarzyna, Pruszczyk, Piotr, Skoczylas, Ilona, Lewicka, Ewa, Blaszczak, Piotr, Karasek, Danuta, Kusmierczyk-Droszcz, Beata, Mizia-Stec, Katarzyna, Kaminski, Karol, Jachec, Wojciech, Peregud-Pogorzelska, Malgorzata, Doboszynska, Anna, Gasior, Zbigniew, Tomaszewski, Michal, Pawlak, Agnieszka, Zablocka, Wieslawa, Ryczek, Robert, Widejko-Pietkiewicz, Katarzyna, Kasprzak, Jaroslaw D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316841/
https://www.ncbi.nlm.nih.gov/pubmed/35886278
http://dx.doi.org/10.3390/ijerph19148423
Descripción
Sumario:We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within the National Health Fund program and reported in the national BNP-PL database. Updated records of 1704 BNP-PL pts collected between March and December 2020 were analyzed with regard to incidence, clinical course and mortality associated with COVID-19. Clinical characteristics of the infected pts and COVID-19 decedents were analyzed. The rates of new diagnoses and treatment intensification in this period were studied and collated to the proper intervals of the previous year. The incidence of COVID-19 was 3.8% (n = 65) (PAH, 4.1%; CTEPH, 3.2%). COVID-19-related mortality was 28% (18/65 pts). Those who died were substantially older and had a more advanced functional WHO class and more cardiovascular comorbidities (comorbidity score, 4.0 ± 2.1 vs. 2.7 ± 1.8; p = 0.01). During the pandemic, annualized new diagnoses of PH diminished by 25–30% as compared to 2019. A relevant increase in total mortality was also observed among the PH pts (9.7% vs. 5.9% pre-pandemic, p = 0.006), whereas escalation of specific PAH/CTEPH therapies occurred less frequently (14.7% vs. 21.6% pre-pandemic). The COVID-19 pandemic has affected the diagnosis and treatment of PH by decreasing the number of new diagnoses, escalating therapy and enhancing overall mortality. Pulmonary hypertension is a risk factor for worsened course of COVID-19 and elevated mortality.